A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.

Autor: Doijen J; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: JDoijen@its.jnj.com., Heo I; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: IHeo@its.jnj.com., Temmerman K; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KTemmer2@ITS.JNJ.com., Vermeulen P; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: PVERMEUL@its.jnj.com., Diels A; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: ADIELS@its.jnj.com., Jaensch S; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: SJAENSCH@its.jnj.com., Burcin M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: MBurcin@ITS.JNJ.com., Van den Broeck N; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: NVanden6@ITS.JNJ.com., Raeymaekers V; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: VRaeymae@ITS.JNJ.com., Peremans J; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: jpereman@ITS.JNJ.com., Konings K; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KKoning1@ITS.JNJ.com., Clement M; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mcleme12@its.jnj.com., Peeters D; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: DPEETER1@its.jnj.com., Van Loock M; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvloock@its.jnj.com., Koul A; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: AKOUL@its.jnj.com., Buyck C; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: CBUYCK@its.jnj.com., Van Gool M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvgool2@its.jnj.com., Van Damme E; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: evandamm@its.jnj.com.
Jazyk: angličtina
Zdroj: Antiviral research [Antiviral Res] 2024 Feb; Vol. 222, pp. 105789. Date of Electronic Publication: 2023 Dec 27.
DOI: 10.1016/j.antiviral.2023.105789
Abstrakt: The recent pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a major threat to global health. Although the World Health Organization ended the public health emergency status, antiviral drugs are needed to address new variants of SARS-CoV-2 and future pandemics. To identify novel broad-spectrum coronavirus drugs, we developed a high-content imaging platform compatible with high-throughput screening. The platform is broadly applicable as it can be adapted to include various cell types, viruses, antibodies, and dyes. We demonstrated that the antiviral activity of compounds against SARS-CoV-2 variants (Omicron BA.5 and Omicron XBB.1.5), SARS-CoV, and human coronavirus 229E could easily be assessed. The inclusion of cellular dyes and immunostaining in combination with in-depth image analysis enabled us to identify compounds that induced undesirable phenotypes in host cells, such as changes in cell morphology or in lysosomal activity. With the platform, we screened ∼900K compounds and triaged hits, thereby identifying potential candidate compounds carrying broad-spectrum activity with limited off-target effects. The flexibility and early-stage identification of compounds with limited host cell effects provided by this high-content imaging platform can facilitate coronavirus drug discovery. We anticipate that its rapid deployability and fast turnaround can also be applied to combat future pandemics.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JD, IH, KT, PV, AD, SJ, MB, DP, MVL, AK, CB, MVG, and EVD are employees of Janssen Pharmaceutica NV, part of Johnson and Johnson, and some of the authors hold shares or share options from Johnson and Johnson as part of their employee remuneration. NVdB, VR, JP, KK, and MC are employees of Charles River Laboratories, which is a contractor of Janssen Pharmaceutica NV.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: